e-therapeutics plc announced a strategic collaboration with Arcturis Data Limited. The companies will integrate Arcturis' Real-World Evidence (RWE), which utilises a platform comprised of high quality, clinically-rich real-world data, and analytical expertise derived from their unique access to anonymised patient data with e-therapeutics' computational biology platform, HepNettm. The collaboration will focus on delivering novel insights to support innovative therapies for patients with metabolic dysfunction and associated fatty liver disease, including nonalcoholic steatohepatitis (NASH).

Arcturis' RWE outputs will be analysed by e-therapeutics using HepNettm, its proprietary suite of artificial intelligence (AI)-driven algorithms and hepatocyte-centric data sources, to drive the discovery and development of innovative RNAi medicines for the treatment of NASH and related disorders. Under the terms of the agreement, e-therapeutics will have exclusive rights to nominate novel gene targets derived from the collaboration to prosecute genetic medicines using its GalOmictm RNAi platform.